Introduction: Worldwide, thalassemia is one of the most common genetic diseases. It affects peoples who originate from the Mediterranean areas through the Middle East to the Indian subcontinent and Southeast Asia. The thalassemia syndromes are broadly classified into two groups: α-thalassemia, in which the α-globin chain synthesis is defective; and β-thalassemia, which results from defective β-globin chain synthesis. α-thalassemia is most commonly caused by gene deletions that affect one or both of the duplicated α-globin loci. The severe form of α-thalassemia, common in Southeast Asia,
is caused by deletion of the duplicated α-globin genes, and the majority of homozygous fetuses die at the third trimester of pregnancy or at birth. In β-thalassemia the common molecular defects are the results of some mutations (point mutations or small deletions) that affect the transcription, splicing, or translation of the mRNA. Newborns with homozygous β-thalassemia are healthy, but as the hemoglobin switches from fetal to adult hemoglobin synthesis just after birth, the lack of β-globin chain synthesis results in the development of progressive anemia. In these patients the degree of anemia may vary depending on the degree of β-globin chain deficiency, but the majority of them have severe anemia requiring life-long blood transfusions and, consequently, iron chelation. Hence, β-thalassemia represents a severe health problem and many therapeutic strategies have been attempted.

Cure of β-thalassemia can be achieved by bone marrow or cord blood transplantations if histocompatible donors are available. However, since these patients’ families are usually small, perfectly histocompatible donors are not commonly found. In addition, graft versus host disease of variable severity usually follows and complicates the clinical course of these transplantations. The other approach of curative treatment of β-thalassemia consists in the gene therapy, but this approach is only at the beginning and till now very few patients have been treated; furthermore, this treatment is not on the point of receiving a marked clinical development in the next years.

An alternative treatment of β-thalassemia consists in the pharmacological stimulation of fetal hemoglobin (HbF) synthesis. In humans, hemoglobin switch from HbF to adult hemoglobin (HbA) occurs in the period around birth as a result of γ- to β-globin gene switching. This switching requires developmental stage-specific changes in the expression/function of transcription factors and chromatin remodeling activities that induce repression of γ-globin gene expression and/or induction of β-globin gene expression. HbF is synthesized at very low levels in adults, representing less than 1% of total hemoglobin. Moreover, the level of HbF is inherited as a quantitative trait and is of enormous clinical relevance, given its role in ameliorating the severity of the main hemoglobin diseases, including β-thalassemia and drepanocytosis. Recent genome-wide association studies have identified three major loci containing a set of five common single-nucleotide polymorphisms (SNPs) that account for ≥20% of the variation in HbF levels. Importantly, several of these variants predict the clinical severity of sickle cell disease and of β-thalassemia. The SNP with the largest effects on HbF synthesis is located in the second intron of a gene present on chromosome 2, encoding BCL11A. A recent study has provided clear evidence that BCL11A is an important regulator of HbF expression. BCL11A acts as a repressor of HbF synthesis and its expression is low in fetal erythroid cells, is abundant in adult erythroid cells; downregulation of BCL11A in adults erythroid cells leads to a remarkable HbF expression. Another SNP that plays an important role in the control of HbF synthesis is located at the level of HBS1L-MYB intergenic region on chromosome 6q23: this locus contains regulatory sequences that play an important role in the control of HbF synthesis and hematopoiesis by controlling MYB expression.

The γ-globin gene transcription is controlled by complex molecular mechanisms involving both cis-acting elements, represented by specific nucleotide sequences, such as Locus Control Region (LCR) and trans-acting elements, such as transcription factors and chromatin remodeling activities. The human β-globin LCR was functionally defined as a DNA regulatory region conferring high levels of erythroid-specific expression to a cis-linked gene in a copy-dependent manner, which is independent of the integration site. GATA-1, EKLF and NF-E2 are the best known tissue-specific transcription factors involved in the transcriptional control of β-like globin genes. GATA-1 and EKLF transcription factors are essential for an active chromatin hub (ACH) formation.

Important informations on cis-elements regulating γ-globin gene expression derive from the analysis of the mutations occurring at the β-globin locus in patients with increased HbF (Hereditary Persistence of Fetal Hemoglobin) (reviewed in 12). Two types of HPFH have been identified: non-deletion and deletion-type HPFH. Non-deletion HPFHs are due to mutations occurring in either the γ or β-globin gene promoters, thus resulting in continued HbF synthesis in adult life. These non-deletion HPFH mutations are clustered in three regions of the γ-globin promoters, at the level of the positions -200, -175 and -115 relative to the transcription site. The increased HbF synthesis observed in adults carrying non-deletion HPFH mutations are due to either a decreased binding of transcription repressors inhibiting γ-globin gene expression or to the generation of binding sites that
potentiate the binding of a transcriptional complex increasing \(\gamma\)-globin gene transcription. On the other hand, the analysis of the DNA deletions as well as of the phenotype of deletion-type HPFH has provided important information on the existence of DNA sequences of the \(\beta\)-globin gene cluster affecting \(\gamma\)-globin gene expression. In the African type of deletion HPFH, large deletions have been observed involving intergenic \(\gamma\)-\(\delta\) sequences and the entire \(\beta\) and \(\delta\) genes. The phenotype of these HPFH forms is seemingly related to the juxtaposition of enhancer elements, normally located downstream of the globin locus, and the HPFH breakpoint exerting a positive stimulatory effect on \(\gamma\)-globin transcription\(^{14}\). The analysis of the gene deletion occurring in \(\delta\beta\) thalassemia and, particularly in \(\delta\beta^{0}\) Corfu deletion strongly supports the notion that intergenic \(\gamma\)-\(\delta\) sequences play a key role in the adult \(\gamma\)-globin reactivation.

In addition to genetic elements present in the \(\beta\)-globin locus, also genetic elements present outside this locus control the level of HbF synthesis during the adult life\(^{7,10}\). These genetic elements contribute to inter-individual variation in HbF expression representing a heritable disease modifier\(^{12}\). Three major loci – Xmn1-HBG2 single nucleotide polymorphism, HBS1L-MYB intergenic region on chromosome 6q, and BC11A- contribute to HbF variation in healthy European Caucasians and \(\beta\)-thalassemia and sickle cell traits\(^{15}\). These HbF quantitative trait loci and others not yet discovered, besides accounting for the common HbF variation in healthy adults, play also an important role in the variation of HbF production in response to erythropoietic stress, and possibly, in the capacity to respond to pharmacological stimulators of HbF synthesis\(^{16}\). It is of interest to note that two of these quantitative trait loci include oncogenes, emphasizing the importance of cell proliferation and differentiation as an important contribution to the HbF phenotype\(^{17}\).

Finally, an important role in the control of globin gene expression is played also by chromatin epigenetic changes. The main chromatin epigenetic changes occur at the level of core histones and consist in covalent modifications such as acetylation, methylation, and phosphorylation. Among these modifications a relevant role is played by histone acetylation in the control of \(\gamma\)-globin gene expression: active \(\gamma\)-globin genes are highly acetylated, while reactive \(\gamma\)-globin genes are scarcely or only mildly acetylated\(^{18}\). Histone methylation plays also an important role in \(\gamma\)-globin gene expression: a low histone methylation at the level of the \(\gamma\)-globin gene promoter is associated with elevated HbF synthesis, while a high level of histone methylation is linked to repression of HbF synthesis\(^{19}\).

**Chemical inducers of HbF synthesis:** The analysis of the molecular mechanisms underlying hemoglobin switching and, particularly \(\gamma\)-globin gene expression, have greatly contributed to the identification, study and possible clinical development of chemical compounds able to reactivate HbF synthesis in adult erythroid cells. A fundamental input to the search of efficient HbF chemical inducers came from the observation, made several decades ago, that HbF may have a protective effect in sickle cell anemia and \(\beta\)-thalassemia\(^{20}\).

During the last 30 years a considerable number of pharmacological agents able to reactivate HbF synthesis have been identified. Some of these agents have been introduced for the treatment of sickle cell anemia and \(\beta\)-thalassemia. According to their mechanism of action these compounds have been classified in various groups: hypomethylating agents, histone deacetylase inhibitors and hydroxyurea. For the analysis of the chemical structure and the biologic properties of these HbF inducers the readers may refer to some recent reviews\(^{21,20,22}\).

The past experimental and clinical observations in the treatment of hemoglobinopathies supported the basic conception that these chemical agents represent a rational approach for sickle cell anemia and \(\beta\)-thalassemia therapy. However, it must be pointed out that, while the effect of these pharmacological treatments on sickle cell anemia was clear, their benefit on the clinical course of \(\beta\)-thalassemia was only limited. The discrepancy between these two hemoglobinopathies in the response to HbF inducers may be mainly related to the higher level of HbF required in \(\beta\)-thalassemia to achieve clinical results comparable to those observed in sickle cell anemia. Furthermore, it was recently suggested that the limited clinical response to \(\gamma\)-globin inducers, observed in the majority of \(\beta\)-thalassemic patients, may be also a reflection of unfavorable effects of these agents on the other globin genes (i.e., increased \(\alpha\)-globin synthesis)\(^{23}\). This observation suggests that other agents able to induce higher HbF levels are required for an efficient \(\beta\)-thalassemia treatment.

Recently, the gene therapy approach was also used to increase the level of HbF synthesis in
Figure 1. Schematic representations of the SCF/c-kit cell signaling. The main pathways activated by the activation of the c-kit receptor are outlined. The pathways seemingly involve in HbF reactivation are outlined.

β-thalassemic erythroid cells. Particularly, it was shown that amelioration of a murine model of β-thalassemia can be achieved through in vivo drug selection of hematopoietic stem cells transduced with a dual γ-globin/methylguanine methyltransferase lentiviral vector.

In the present review we describe the biologic properties of Stem Cell Factor (SCF also known as Kit Ligand), a cytokine that, besides sustaining survival, stimulating hematopoietic progenitor cell proliferation and enhancing proliferative response to erythropoietin, at pharmacological doses acts as a potent stimulator of HbF synthesis in adult erythroid cells.

Role of SCF in the control of erythropoiesis:
Erythropoiesis is subject to a complex regulation via a network of cytokine receptor systems that act at the level of various stages during erythroid differentiation and maturation. Erythropoietin (Epo) is an essential key regulator of erythropoiesis, mainly acting as a cytokine promoting the survival and proliferation of late erythroid progenitors (CFU-E). The growth of early erythroid progenitors (BFU-E) is promoted by various interleukins, including IL-3, IL-11, IL-4 and IL-12. In addition, erythropoiesis is regulated by a series of receptor tyrosine kinases (RTKs). Among them, a relevant role is played by RON (c-met-related tyrosine kinase) and its ligand that exert a stimulatory effect on BFU-E proliferation, Insulin-Like-Growth Factor and its receptors stimulating late stages of erythropoiesis and EPHB4 that exerts a stimulatory effect on erythropoiesis at various differentiation stages.

Particularly, an important role in the control of erythropoiesis is played by SCF and its receptor (SCF-R or c-kit). The initial observations leading to discover a role of this cytokine in erythropoiesis derived from the analysis of mice exhibiting mutations in the SCF gene, Steel (Sl), or its receptor c-kit: these mice develop severe anemia characterized by depressed erythropoiesis. Particularly, mice that lack the expression of c-kit
C-kit is expressed on the majority of CD34+ hematopoietic progenitors and its expression is maintained at high levels during the stages of differentiation from BFU-E to CFU-E; at later stages of differentiation during the maturation of CFU-E, c-kit expression progressively declines and disappears in polychromatophilic and orthochromatic erythroblasts. These findings imply that SCF may exert effects on erythroid cells during early and late stages of erythroid differentiation and may act also on immature erythroid precursors. Repression of c-kit expression and signaling at late stages of erythroid differentiation is mediated by the transcription factor GATA-1 through direct interaction with the c-kit gene promoter. Particularly, it was shown that during early stages of erythroid differentiation the c-Kit gene promoter is occupied by the GATA-2 transcription factors that exerts a stimulatory role on the transcription of this gene; upon cell differentiation, GATA-1 displaces GATA-2 and triggers a repressive effect on c-kit gene transcription. Other studies have shown that the transcription factor PLZF is required, together with GATA-2, for allowing elevated level of c-Kit expression during early stages of erythroid differentiation and the microRNA 221 and 222 are involved in c-kit downmodulation occurring at late stage of erythroid differentiation.

SCF/c-kit interactions lead to c-kit autophosphorylation at the level of up to 21 c-kit phospho-tyrosine (PY) docking residues for SH2 and PTB domain proteins. Using suitable cell line models, studies on c-kit PY mutants have defined the specificities of these PY residues: Y719 binds p85-PI3K; Y728 binds phospholipase C-γ; Y702 and Y934 bind Grb2 and Grb7 adaptor binding proteins; juxtamembrane Y567 and Y569 sites bind SRC family kinases and, through this mechanism, activate key survival and proliferation pathways. To define the biologic function of the various PY residues of c-kit, mice carrying tyrosine-to-phenylalanine substitution mutations have been generated. These studies have shown that Y569 and Y719 residues are not essential for erythropoiesis. However, a recent study provided evidence that in kitY567F/Y567F mice, steady state erythropoiesis was unperturbed, while recovery from chemically-induced anemia was markedly impaired, thus indicating a key role of c-kit in the control of stress erythropoiesis.

These observations clearly showed that c-kit signalling is important for normal erythropoiesis and, particularly for stress erythropoiesis. On the other hand, numerous in vitro and in vivo experiments have shown that SCF and Epo co-administration results in a stimulation of erythropoiesis and BFU-E and CFU-E colony formation: particularly, in vitro administration of SCF together with Epo resulted in a marked enhancement of erythroid proliferation, associated with a delay in erythroid maturation.

Other studies have suggested that SCF could potentiate the stimulation of some transduction pathways activated by Epo. The studies aimed at elucidating the synergistic interaction between SCF and Epo have proposed two main underlying mechanisms. The first mechanism suggests that the synergism is mainly related to the sequential role of SCF and Epo during erythroid differentiation. The second mechanism suggests that SCF and Epo have simultaneous, joint effects on the same individual cells at a specific stage of erythroid development (proerythroblast stage). In this context, recent
studies support a model of erythroid differentiation in which the effects of SCF and Epo on individual erythroid progenitors/precursors are mainly sequential and co-signaling (i.e., signaling by both cytokines on the same cells, resulting or not in crosstalk between pathways) has only a limited contribution to the final erythroid output.

Kit and EpoR mediated co-signaling is essential for normal erythroid cell expansion; however, the intracellular signaling that contributes to cooperative signaling have been only in part elucidated. Studies with mutants of c-kit and EpoR suggest that kit and EpoR mediated co-signaling requires intracellular tyrosine residues: particularly, tyrosine residues that bind Src kinases in the kit receptor (i.e., Y^567 and Y^569) appear to be sufficient for kit signaling as well as co-signaling with EpoR.

Activation of PI3K is essential for proliferation of erythroid cells. Activated PI3K generates PIP3, which serves as an anchor for multiple PH-domain-containing proteins, such as protein kinase B (PKB). Although both SCF and Epo induce activation of PI3K in erythroblasts, the efficiency with which respective downstream signaling pathways are activated shows large differences: particularly, the activation of PKB is more responsive to SCF than to Epo. PI3K stimulates the activation of mTOR and subsequent release of the cap-binding translation initiation factor 4E (eIF4E) from the 4E-binding protein 4EBP, which controls the recruitment of structured mRNA to polysomes. Enhanced expression of the eIF4E renders erythroblast proliferation independent of PKB. The activation of eIF4E by SCF determines the selective association with polysomes of some mRNAs, whose translation is then stimulated. One of these mRNAs is represented by Immunoglobulin Binding Protein 1 (IGBP1): this gene is involved in cell renewal and to the attenuation of the molecular mechanisms responsible for the stimulatory role of glucocorticoids on erythropoiesis are not precisely determined, but they seem to involve an up modulation of c-kit and c-myc expression. Interestingly, p53 antagonizes the stimulatory activity of glucocorticoids on erythropoiesis.

The mechanism of the cooperative signaling between Epo, KL and glucocorticoids was explored by micro array profiling. This type of analysis provided evidence that the majority of the genes are modulated by glucocorticoids only in the presence of Epo and KL, suggesting that these hormones function in the context of large transactivation complexes. The basic effect of glucocorticoids seems to be mainly related to the induction of genes involved in cell renewal and to the attenuation of genes exerting a growth-inhibitory effect. In other words, glucocorticoids act to enhance c-kit signaling and to activate the stimulatory role of SCF on erythropoiesis more efficiently than the soluble SCF form. In line with these observations recent studies performed on in vitro generated CFU-Es provided clear evidence that SCF, but not Epo, is able to induce the phosphorylation of MEK. This MEK activation does not seem to be involved in the stimulatory effect of SCF on erythroid cell proliferation, but is involved in mediating specific pathway of gene activation induced by SCF.

Furthermore, SCF stimulates EpoR expression and Stat5 expression, although it was unable to phosphorylate and then to activate this transcription factor. Recent studies confirmed that SCF was unable to activate Stat-5 phosphorylation and products of Stat-5 target genes induced by Epo act to enhance c-kit signalling. Stat-5 seems to be essential for stress erythropoiesis and for mediating the response to anemia: EpoR and KIT-induced Stat5 signals induce factors (such as Bel-x and oncostatin-M) required for the survival of erythroid progenitors/precursors.

Recent studies suggest that, in addition to Epo and SCF, also glucocorticoids have a remarkable effect on erythropoiesis. These hormones act through nuclear receptors and recent investigations indicate that mice deficient in glucocorticoid receptor expression exhibit a complete loss of stress erythropoiesis, i.e., the capacity to respond with an increased erythropoietic production to stress conditions, such as erythrolysis or hypoxia. In vitro studies have shown that glucocorticoids are able to exert a marked stimulatory effect on erythropoiesis: their effect, however, is evident only when erythroid cells are grown in the presence of both Epo and SCF. The molecular mechanisms responsible for the stimulatory role of glucocorticoids on erythropoiesis are not precisely determined, but they seem to involve an up modulation of c-kit and c-myc expression. Interestingly, p53 antagonizes the stimulatory activity of glucocorticoids on erythropoiesis.
addition to glucocorticoids also androgens exert a stimulatory effect on erythroid proliferation; however, since normal erythroblasts lack androgen receptors, the stimulatory effect on these receptors on erythropoiesis seems to be related to the usurpation of other nuclear hormone receptors by androgens53.

The rapid response to anemia does not involve only SCF, but also Bone Morphogenetic Protein 4 (BMP4). BMP4 is rapidly, and induced erythropoiesis cells in the red splenic pulp of anemic animals in response to acute anemia and was found to stimulate immature progenitors to give rise to Epo-responsive progenitors. Studies in animal models have shown that erythroid response to acute anemia involves the rapid expansion of a specialized population of erythroid progenitors, termed stress BFU-E, mediated by BMP454. SCF and hypoxia synergize with BMP4 to promote the expansion and differentiation of stress BFU-E during the recovery from acute anemia55. More recently, it was demonstrated that the response of erythroid progenitors to BMP4 is regulated by hedgehog signaling56.

Effect of SCF Factor on Hb F synthesis: Considering the pronounced effects of SCF on erythropoiesis it seemed important to evaluate a possible effect of this cytokine on HbF synthesis. The majority of these studies have been carried out by investigating SCF effect in adult erythroid cell cultures.

In this regard, the evaluation of cytokine effects on erythrobalt HbF synthesis requires a stringent methodology, involving the use of purified hemopoietic progenitors (usually human CD34+ purified cells) and serum-free conditions57-60. In fact, fetal calf serum, routinely used for culture of human hemopoietic cells, contains factors able to stimulate HbF synthesis57-60. Furthermore, accessory cells present in cultures of unpurified hemopoietic progenitors, may affect or modify the effect of exogenous cytokines on HbF synthesis.

In an initial study Miller et al. observed a clear stimulation of HbF synthesis induced by SCF in normal (from 0.5% to 6%) and sickle cell anemia (from 4 to 6.8%) BFU-Es grown under serum-free conditions61. These findings were confirmed and extended by Peschle et al. using purified hemopoietic progenitors grown under serum-free conditions either in semisolid medium to generate BFU-E or in liquid suspension cultures allowing the selective growth of erythroid cells62. Using these unilineage culture conditions it was observed that SCF at optimal concentrations (i.e., 100 ng/ml) elicited a marked enhancement of HbF synthesis levels up to 20%62. The stimulatory effect of SCF on HbF production could be mediated either by an effect on the BFU-E HbF synthesis program or by the recruitment of BFU-Es with an elevated HbF production potential. Experiments carried out on single BFU-Es provided evidence in favor of a direct, dose-related stimulatory effect of SCF on HbF synthesis reactivation63. In this same study it was shown that SCF was able to synergize with sodium butyrate to enhance HbF synthesis: in fact, the combined addition of the two agents together induced HbF synthesis levels up to 40-43% in normal adult erythroid cells63.

Wojda et al. comparatively analyzed twelve cytokines acting on erythropoiesis and confirmed that, among them, only SCF was able to significantly enhance HbF synthesis64. The capacity of SCF to reactivate HbF synthesis in adult erythroblasts was correlated to the presence of c-kit on erythroid progenitors/precursors: in fact, the delayed addition of SCF to erythroid cultures was active in inducing a marked enhancement of HbF synthesis only if added on erythroid cell progeny c-kit64. Subsequent studies have shown the synergistic effect between SCF and other agents in stimulating HbF synthesis. Two molecules, Transforming Growth Factor-β (TGF-β) and corticosteroids, potentiate the effect of SCF on HbF synthesis. Thus, despite their opposite effects on erythroid cell growth, SCF and TGF-β had synergistic effects with respect to HbF synthesis65.

In erythroid cultures supplemented with Epo+SCF+TGF-β about a 40% of HbF synthesis was observed, with a pancellular distribution of HbF in erythroid cells65. The evaluation of glucocorticoids effects on HbF synthesis, alone or in cooperation with SCF, was prompted from studies showing that corticosteroids, such as dexamethasone, cooperate with Epo and SCF to enhance and sustain the proliferation of erythroid progenitors66. Dexamethasone when added together with Epo and SCF enhanced HbF synthesis up to 55%; furthermore, analysis of erythroid cultures of sibling BFU-Es showed that the stimulatory effect of Dexamethasone+SCF was related to the modulation of β-globin expression rather than to recruitment of BFU-Es with elevated HbF synthetic potential67.

The effect of SCF was recently investigated in cultures of β-thalassemic erythroid cells. In erythroid cultures of β-thalassemic patients, addition of SCF (in the presence of Epo),
remarkably stimulated cell proliferation (3-4 logs over control cultures), decreased the percentage of apoptotic and dyserythropoietic cells and markedly increased γ-globin synthesis, reaching levels 3-fold higher than in control cultures (from 27% to 81%)\(^{65}\). These studies indicate that in β-thalassemia SCF induces an expansion of effective erythropoiesis and the reactivation of HbF synthesis up to fetal levels and may hence considered as a therapeutic agent for this disease\(^{68}\).

The mechanisms through which SCF stimulates HbF synthesis in adult erythroid cells is largely unknown. It is evident that the mechanism of HbF induction by SCF must be related to one or several signaling pathways induced by the interaction of this cytokine with its receptor c-kit. In this context, Bhanu et al\(^{69}\) evaluated the effect of inhibitors of various signaling pathways, including JAK2, PKC, PI3K, p38MAPK, guanylate cyclase and MEK inhibitors. Only MEK inhibitors elicited a pronounced inhibitory effect on HbF synthesis, thus indicating that phosphorylation of ERK-1/ERK-2 MAPK plays an essential role in the mechanisms through which SCF activates γ-globin gene expression in adult erythroid cells. At variance with SCF, the large majority of the other HbF chemical inducers activate p38 MAPK cell stress signaling pathway and this pathway is required for their stimulatory effect on HbF synthesis\(^{70}\).

Among the large number of proteins binding to the γ-globin promoter region, it was recently demonstrated that stage-specifically expressed nuclear receptor chicken ovalbumin upstream promoter- transcription factor II (COUP-TFII) and the direct repeat erythroid definitive binding protein TR2/TR4, are implicated in SCF-mediated HbF reactivation\(^{67}\). Particularly, it was shown that COUP-TFII expression is suppressed by SCF through phosphorylation of serine/threonine phosphatase and this event is required for SCF-induced HbF reactivation\(^{71}\). This finding may be linked to the previous studies on the role of ERK1/2 on SCF-mediated HbF induction. In fact, SCF, through stimulation of ERK1/2 MAPK signaling pathway, regulates the downstream repressor COUP-TFII by inhibiting serine/threonine phosphatase 2A activity and the decreased COUP-TFII expression resulted in γ-globin reactivation\(^{71}\).

Other studies have suggested a possible role of some transcription factors whose expression is induced by SCF, such as Id2, Tal-1 and FKLF in mediating the transcriptional activation of the human γ-globin gene \(^{63,67}\). A recent study provided evidence that SCF treatment of adult erythroid progenitors was associated with consistent changes of globin gene histones and with a concomitant transcriptional activation pathway involving reproducible changes in expression of some nuclear transcription factors that are recognized regulators of erythropoiesis or globin genes (MAFF, Id2, HHEX, SOX6 and EGR1)\(^{72}\). Interestingly, in this study an inhibitory effect of SCF on the expression of BCL11A mRNA expression was reported\(^{72}\).

These SCF \textit{in vitro} observations must be extended to \textit{in vivo} studies in order to evaluate optimal doses, schedules of administration and side effects. In this context, combined doses of SCF and Epo have been administered to baboons, achieving up to 20% HbF levels\(^{73}\). Preclinical studies in primates and mice suggested that SCF occasionally causes significant allergic side effects, related to induction of mastocytosis\(^{74,75}\). This was confirmed by subsequent clinical trials in HIV and cancer patients\(^{76,77}\), aplastic anemia\(^{78}\), cord blood transplantation\(^{79}\) and postablative chemotherapy\(^{80}\) specifically, mild allergic reactions (e.g., pruritus, urticaria, cutaneous angioedema) were reported in a minority of patients, while severe ones (e.g., laringospasm) were observed only in exceptional cases. In the most extensive phase 3 trial, SCF was used for stem cell mobilization: patients received recombinant SCF at 20 μg/kg per day for 5 consecutive days and 3 of them reported systemic allergic reactions, resolved after treatment with steroids\(^{81}\). The potential use of SCF for treatment of β-thalassemic or sickle cell anemia patients implies a chronic administration protocol, based on sequential intermittent therapy cycles: this protocol may amplify the potential risk of allergic reactions and must be considered cautiously in view of these possible side effects.

It is of interest to note that recent studies have involved the SCF/c-kit system in the mechanism of physiologic hemoglobin switching. First, it was observed that the level of c-kit and SCF expression is particularly elevated during embryonic/fetal life at the level of tissues involved in hematopoiesis (AGM region and fetal liver)\(^{82}\). Second, it was reported that cord blood serum contains clearly higher SCF levels than adult serum, a phenomenon seemingly related to the capacity of human umbilical vein endothelial cells to release large amounts of SCF\(^{83,84}\). Third, c-kit expression on cord blood CD34+ cells gradually declines: this decrease is directly related to the decline of HbF content. This decline of c-kit expression is paralleled by a concomitant gradual decrease of SCF levels (Gabbianelli M et al, unpublished observations).
Altogether these observations suggest that a decline of kit activity could play a role in the mechanism of perinatal HbF→HbA hemoglobin switching. In line with this hypothesis, addition of SCF in cord blood BFU-E cultures reactivates HbF production in a dose-dependent fashion, almost up to the pre-switch levels (Gabbianelli M et al, unpublished observations). The mechanisms underlying the modulation of c-kit expression during ontogenesis could be, at least in part, related to the c-kit suppressing miR221/miR222 complex, whose levels increased during development (Gabbianelli et al, unpublished observations). Interestingly, a recent study by Bianchi et al suggested that the hypoxia-associated miR210 might be involved in increased expression of γ-globin genes in differentiating erythroid cells. At the moment it is unknown whether miR210 expression is controlled by SCF and is modulated in erythroid cells during ontogenesis, and particularly during the Hb switching period.

References

1. Weatherall D, Clegg J. The thalassemia syndromes. Wiley-Blackwell, New York, 2nd ed., 2001.
2. Locatelli F. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137-2143.
3. Bank A, Doriao R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005; 1054: 308-316.
4. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006; 107: 435-443.
5. Patinois GP, De Krom M, De Boer E. Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes Dev 2004; 18: 1495-1509.
6. Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science 1975; 188: 361-363.
7. Lettge G, Sankaran VG, Bezzer MA, Araujo AS, Uda M, Sanna S, Cao A, Schlessinger D, Costa FF, Hirschhorn JN, Orkin SH. DNA polymorphism at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008; 105: 11869.
8. Uda M, Galanelllo R, Sanna S, Lettge G, Sankaran VG, Chen W, Usula A, Busonero F, Maschio A, Albugi A, Piras MG, Sestu N, Bai S, Dei M, Mulas A, Chrispon L, Naita S, Sunis J, Deiana M, Nagaraja R, Perese L, Satta S, Cipollina MD, Sollano C, Moj P, Hirschhorn JN, Orkin JN, Abecasis GR, Schlessinger D, Cao A. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of the type 2 beta-thalassemia. Proc Natl Acad Sci USA 2008; 105: 1620.
9. Menezel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelinka D, Boland A, Rooks H, Best S, Spector TD, Farrall M, Lthrop M, Thein SL. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007; 39: 1197.
10. Sankaran VG, Menne TF, Xu J, Akie TE, Lettge G, Handel BV, Miikolla H, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008; 322: 1839-1842.
11. Wahlberg K, Jiing J, Rooks H, Javvaid K, Matsuda F, Yamaguchi M, Lthrop M, Thein SL, Best S. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 2009; in press.
12. Manca L, Masala B. Disorders of the synthesis of human fetal hemoglobin. Ann NY Acad Sci 1998; 850: 38-44.
13. Katsaouni AZ, Langeveld A, Wai A, Drobek D, Grosfeld V, Anagnost N, Stroubolou J. Persistent γ-globin gene expression in adult transgenic mice is mediated by HPFH-2, HPFH-3 and HPFH-6 breakpoint sequences. Blood 2003; 102: 3412-3419.
14. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Brit J Haematol 2009; 145: 455-467.
15. Ma Q, Wyszyński DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT and Steinberg MH. Foetal hemoglobin in sickle cell anemia: genomic remnants of response to hydroxyxyurea. The Pharmacogenomics Journal 2007; 7: 386-394.
16. Menzel S, Thein SL. Genetic architecture of hemoglobin F control. Curr Opin Hematol 2009; 16: 179-186.
17. Schubeler D, Francastel C, Cimborra DM, Reik A, Martin DJ, Groudine M. Nuclear localization and histone acetylation: a pathway for chromatin opening and transcriptional activation of the human beta-globin locus. Genes Dev 2000; 14: 940-950.
18. Mabaera R, Richardson CA, Johnson K, Han M, Fiering S, Loery CH. Developmental- and differentiation-specific patterns of human α/γ-globin promoter DNA methylation. Blood 2007; 110: 1343-1352.
19. Watson J, Stahnaw AM, Bilello FP. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 1948; 215: 419-423.
20. Gambari R, Fibaec E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassasemia. Curr Med Chem 2007; 14: 199-212.
21. Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 2009; 88: 505-528.
22. Fathallah H, Toher A, Babazarbachi A, Atweh GF. Differences in response to fetal hemoglobin induction therapy in β-thalassemia and sickle cell disease. Blood Cells Mol Dis 2009; 43: 58-62.
23. Zhao H, Persini TIA, Nasimuzzaman M, Mether P, Hargrove PW, Pesons DA. Amelioration of murine β-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both γ-globin and the GMGT drug-resistance gene. Blood 2009; 113: 5747-5756.
24. van den Akker E, van Dijk T, Parren-van Amelsvoort M, Grossman KS, Schaepera U, Toney-earley K, Waltz SE, Lowenberg B, von Lindern M. Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 2004; 103: 4457-4465.
25. Miyagawa S, Kobayashi M, Konishi N, Satou T, Ueda K. Insulin and insulin-like growth factor I support the proliferation of erythroid progenitor cells in bone marrow through the sharing of receptors. Br J Haematol 2000; 109: 555-562.
26. Suenobu S, Takakura N, Inada Y, Yuasa H, Zhang XQ, Sakano S, Oike Y, Suda T. A role of EphB4 receptor and its ligand, ephrin-B2, in erythropoiesis. Biochem Biophys Res Commun 2002; 293: 1124-1131.
27. Chui DH, Liao SH, Walker K. Fetal erythropoiesis in steel mice. Proc Natl Acad Sci 2004; 101: 2137-2141.
28. Waskow C, Terszowski G, Costa C, Gassmann M, Rodelwald HR. Rescue of lethal c-Kir™ mice by erythropoietin. Blood 2004; 104: 1688-1695.
30. Testa U, Fossati C, Samoggia P, Mariani G, Hassan HJ, Sposi NM, Guerrero R, Rosato V, Gabbianelli M, Pelosi E, Valtieri M, Peschle C. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood 1996; 88: 3391-3406.

31. Munugalavadla V, Dore LC, Tan BL, Hong L, Vishnu M, Weiss MJ, Kapur R. Repression of c-Kit and its downstream substrates by GATA-1 cells proliferation during erythroid maturation. Mol Cell Biol 2005; 25: 6747-6759.

32. Jing H, Vakoc CR, Ying L, Mandat S, Wang H, Zheng X, Blobel GA. Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus. Mol Cell 2008; 29: 232-242.

33. Spinello I, Quarta MT, Pasquini L, Pelosi E, Petrucci E, Pagliuca A, Castelli G, Mariani G, Diverio D, Foa R, Testa U, Labbaye C. PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis. Oncogene 2009; 28: 2276-2288.

34. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroblastic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086.

35. Agosti V, Korur V, Sathnaryanaya P, Besmer P, Wojcikowski DM. A kit juxtamembrane PY567-directed pathway provides nonredundant signals for erythroid progenitor cell development and erythropoiesis. Exp Hematol 2009; 37: 159-171.

36. Wang W, Horner DN, Chen W, Zandstra PW, Audet J. Synergy between erythropoietin and stem cell factor during erythropoiesis can be quantitatively described without co-signaling effects. Biotechnol Bioengin 2009; 99: 1261-1272.

37. Hong L, Ramadas B, Chen J, Harris C, Wojchikowskie DM, Kapur R. KIT associated intracellular tyrosines play an essential role in EpoK co-signaling. Cell Signal 2008; 20: 1513-1520.

38. Bakker WJ, Blazquez-Domingo M, Kolbuts A, Besooyen J, Dijk TB. FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol 2004; 164: 175-184.

39. Blazquez-Domingo M, Grech G, Vn Linden M. Translation initiation factor 4E inhibits differentiation of erythroid progenitors. Mol Cell Biol 2005; 25: 8496-8506.

40. Grech G, Blazquez-Domingo M, Kolbuts A, Bakker WJ, Mulller EW, Beug H, Von Linden M, van Dijk TB. FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol 2004; 164: 175-184.

41. Sui X, Krantz SB, You M, Zhao Z. Synergistic activation of the Stat5 axis. J Clin Invest 2006; 116: 683-694.

42. Kapur R, Chandra S, Cooper R, McCarthy J, Williams DA, Pircher TJ, Geiger JN, Zhang D, Miller CP, Gaines P, Felli N, Fontana L, Pelosi E, Wacylykk B. The p53 tumor suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO R. 2002; 3: 569-574.

43. Kapur R, Gu F, Sargentu G, Vatsylyuk B. The p53 tumor suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. Proc Natl Acad Sci USA 2009; 106: 2301-2306.

44. Kapur R, Zaner W, Mcllitzer G. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999; 94: 550-559.

45. Gabbianelli M, Testa U, Massa A, Petrucci E, Morsilli O, Peschle C. HIF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with dexamethasone at therapeutic level. Blood 2003; 101: 2826-2833.

46. Gregory G, Bacc S, Egert G, Wacylyk B. The p53 tumor suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO R. 2002; 3: 569-574.

47. Bhanu NV, Trice TA, Lee YT, Gautt NM, Oneal P, Schwartz JD, Noel P, Miller PL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood 2005; 105: 387-393.
66. Von Lindern M, Zauner W, Mellitzer G, Steinlein P, Fritsch G, Huber K, Lowenberg B, Beug H. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999; 94: 550-559.

67. Gabbianelli M, Testa U, Massa A, Morsilli O, Saulle E, Sposi NM, Petrucci E, Mariani G, Peschle C. HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood 2003; 101: 2826-2832.

68. Gabbianelli M, Morsilli O, Massa A, Pasquini L, Cianciulli P, Testa U, Peschle C. Effective erythropoiesis and HbF reactivation induced by kit ligand in β-thalassemia. Blood 2008; 111: 421-429.

69. Bhanu NV, Trice TA, Lee YT, Miller JL. A signaling mechanism for growth-related expression of fetal hemoglobin. Blood 2004; 103: 1929-1933.

70. Mabaera R, West RJ, Canine SJ, Macari ER, Boyd CD, Engman CA, Lowrey CH. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol 2008; 36: 1057-1062.

71. Aerbajinai W, Zhu J, Kunkhaek C, Chin K, Rodgers GP. SCF induces γ-globin gene expression by regulating downstream transcription factor COUP-TFII. Blood 2009; in press.

72. Sripichai O, Kiefer CM, Bhanu NV, Tanno T, Noh SJ, Goh SH, Russell JE, Rognerud CL, Ou CN, Oneal PA, Meier ER, Gantt NM, Byrnes C, Lee YT, Dean A, Miller JL. Cytokine mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming. Blood 2009, in press.

73. Lavelle D, Molokie R, Duckworth J, DeSimone J. Effects of hydroxyurea, stem cell factor, and erythropoietin in combination on fetal hemoglobin in the baboon. Exp Hematol 2001; 29: 156-162.

74. Galli SJ, Iemura A, Garlick DS, Gamha-Vitalo C, Zseo KM, Andrews RG. Reversible expansion of primitive mast cell populations in vivo by stem cell factor. J Clin Invest 1993; 91: 148-152.

75. Ando A, Martin TR, Galli SJ. Effects of chronic treatment with the c-kit ligand, stem cell factor, on immunoglobulin E-dependent anaphylaxis in mice. Genetically mast cell-deficient SI/Sld mice acquire anaphylactic responsiveness, but the congeneric normal mice do not exhibit augmented responses. J Clin Invest 1993; 92: 1639-1649.

76. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183: 2681-2686.

77. Crawford J, Lan D, Erwin R. A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced non-small cell lung carcinoma (NSCLC). Proc Ann Meet Am Assoc Cancer Res 1993;34: 1257a.

78. Usuki K, Iki S, Arai S, Iijima K, Takaku F, Urabe A. Stable response after administration of stem cell factor combined with granulocyte colony-stimulating factor in aplastic anemia. Int J Hematol 2005; 83: 404-407.

79. Wadhwia PD, Lazarus HM, Koc ON. Hematopoietic recovery after unrelated umbilical cord blood allogeneic transplantation in adults treated and in vivo stem cell factor (R-Met Hu SCF) and filgrastim administration. Leuk Res 2003; 27: 215-220.

80. Blaise D, Faucher C, Vey N, Caraux J, Maraninchi D, Chabannon C. Rescue of hemopoiesis by a combination of growth factors including stem cell factor. Lancet 2000; 356: 1325-1326.

81. Shpall EJ, Wheeler CA, Turner SA. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-2501.

82. Teysssier-Le Discorde M, Prost S, Nandrot C, Kiresevbaunm B. Spatial and temporal mapping of c-kit and its ligand, stem cell factor expression during human embryonic hemopoiesis. Brit J Haematol 1993; 107: 247-253.

83. Yamaguchi H, Ishii E, Saito S, Tashiro K, Fujita I, Yoshidomi S, Ohbuto M, Arakawa K, Miyazaki S. Umlilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Brit J Haematol 1993; 94: 606-611.

84. Savas A, Ince S, Coskun M, Durnaz S, Yegin O. Stem cell factor (SCF) levels in newborns. Am J Perinatal 1998;15: 427-429.

85. Broody VC, Kovach NL, Bennet LG, Lin N, Jacobsen FW, Kidd PG. Human umbilical vein endothelial cells display high-affinity c-kit receptors and produce a soluble form of the c-kit receptor. Blood 1994; 83: 2145-2152.

86. Bianchi N, Zuccata C, Lamponti I, Borgatti M, Gambhari R. Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression. BMP Reports 2009; 42: 493-499.